New Zealand markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
8.89+0.36 (+4.22%)
At close: 04:00PM EST
8.78 -0.11 (-1.24%)
After hours: 05:14PM EST

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858 251 4400

Full-time employees223

Key executives

NameTitlePayExercisedYear born
Dr. Barry D. QuartChairman & CEO1.06MN/A1957
Mr. John W. PoyhonenPres & Chief Commercial Officer720.45kN/A1960
Mr. David L. SzekeresExec. VP & COO647.12kN/A1974
Ms. Lisa PerazaVP & Chief Accounting Officer449.06kN/A1977
Ms. Kimberly J. ManhardExec. VP of Drug Devel. & Director727.69k70k1960
Mr. Sean T. RistineSr. VP of HRN/AN/A1970
Dr. Thomas B. OttoboniChief Scientific Officer and Sr. VP of Pharmaceutical & Translational SciencesN/AN/A1959
Mr. Michael E. MathewsSr. VP of Acute CareN/AN/A1963
Dr. Chris M. StorgardChief Medical OfficerN/AN/A1966
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Corporate governance

Heron Therapeutics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 5. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.